CN1857297A - 一种用于治疗微血管循环障碍疾病的药物组合物及其制备方法 - Google Patents
一种用于治疗微血管循环障碍疾病的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1857297A CN1857297A CN 200610081305 CN200610081305A CN1857297A CN 1857297 A CN1857297 A CN 1857297A CN 200610081305 CN200610081305 CN 200610081305 CN 200610081305 A CN200610081305 A CN 200610081305A CN 1857297 A CN1857297 A CN 1857297A
- Authority
- CN
- China
- Prior art keywords
- radix puerariae
- puerariae flavone
- calcium dobesilate
- compositions
- flavone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 230000004089 microcirculation Effects 0.000 title claims abstract description 17
- 230000004064 dysfunction Effects 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 13
- 238000000034 method Methods 0.000 title description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 229930003944 flavone Natural products 0.000 claims description 52
- 235000011949 flavones Nutrition 0.000 claims description 52
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 45
- 150000002212 flavone derivatives Chemical class 0.000 claims description 45
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 45
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims description 37
- 229960005438 calcium dobesilate Drugs 0.000 claims description 37
- 238000011282 treatment Methods 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 28
- 239000008280 blood Substances 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 15
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 7
- 150000002213 flavones Chemical class 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 235000015424 sodium Nutrition 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000219780 Pueraria Species 0.000 abstract 1
- JVEDXKIOAFPPPG-UHFFFAOYSA-L calcium;4-hydroxybenzenesulfonate Chemical compound [Ca+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 JVEDXKIOAFPPPG-UHFFFAOYSA-L 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000007779 soft material Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010038491 Renal papillary necrosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- ZFLASALABLFSNM-QBOHGLHMSA-L carbanide;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-oc Chemical compound [CH3-].[Co+3].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ZFLASALABLFSNM-QBOHGLHMSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 gallate ester Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种用于治疗微血管循环障碍疾病的药物组合物及其制备方法，其特征在于：含有羟苯磺酸钙和葛根黄酮作为药物活性成分，其中羟苯磺酸钙和葛根黄酮的重量配比为：10－1000重量份的羟苯磺酸钙和10－1000重量份的葛根黄酮。
Description
技术领域
本发明涉及一种用于治疗由微血管循环障碍引起的多种疾病的药物组合物及其制备方法。该组合物含有羟苯磺酸钙和葛根黄酮作为药物活性成分，主要用于治疗由微血管循环障碍引起的多种疾病，特别的，主要用于糖尿病引起的视网膜病变，微循环障碍引起的心、脑、肾疾病，如肾小球动脉硬化症以及静脉曲张等综合症的治疗。
背景技术
糖尿病是一组常见的代谢内分泌病，全世界有糖尿病患者1.25亿，我国的糖尿病患者已达4000万。世界卫生组织将糖尿病列为三大疑难病之一，由于糖尿病患者体内血糖浓度较高，过量的葡萄糖经戊糖旁路进行代谢，被醛糖还原酶催化生成山梨醇，而山梨醇可以造成毛细血管细胞和内皮细胞受损；另外患者微血管内皮细胞可生成过多的凝血因子VIII，前列腺环素产生减少，均可促使血小板发生黏附和聚集，促进微血栓形成，另外血糖增高刺激IV型胶质蛋白及粘连蛋白合成增加，硫酸类肝素多糖蛋白构成的负电荷位点数目减少，毛细血管通透性增加。这一系列的原因使糖尿病患者往往伴随较多的并发症，如糖尿病肾病、糖尿病眼病、糖尿病神经病变、糖尿病足、糖尿病心、脑大血管病变等。
同时，其他的一些疾病也直接或间接的导致微血管循环障碍，进而对身体各个器官产生危害，给患者带来了极大的痛苦。
羟苯磺酸钙通过调节微血管壁的生理功能，减低毛细血管的高通透性和减少阻力，降低血浆粘稠度，降低血小板的高聚集性，从而防止血栓形成；通过提高红细胞柔韧性，间接增加淋巴的引流从而减少水肿。羟苯磺酸钙还可以通过抑制血管活性物质(组织胺、5-羟色胺、缓激肽、透明质酸酶、前列腺素)引起的高通透作用，从而改善基底膜胶原的生物合成。因此可以用于微血管循环障碍(毛细血管循环障碍)引起的多种疾病。
中医药在改善血流状态、提高免疫、抗衰老等多途径、多方面、多环节上已经显示出巨大的优势，其毒副作用小，且疗效稳定。
葛根黄酮是从中药葛根中提取的总黄酮，具有降血糖，扩张外周血管，特别是扩张冠状动脉血管、改变高凝聚状态及微循环、抑制血小板聚集等作用。葛根素作为葛根黄酮中的一种，是一个抗氧剂，国外有文献报道，葛根素可有效去除自由基对胰岛细胞的伤害(Puerarin protects rat pancreatic islets from damage byhydrogen peroxide.European Journal of Pharmacology[Eur J Pharmacol]2006 Jan 4；Vol.529(1-3)，PP.1-7)。
由于治疗微循环障碍疾病，特别是糖尿病引起的微循环障碍疾病，是一个极其复杂的过程，单一用药难以取得满意的治疗效果。因此，本发明人从中西医结合的角度，通过大量的实验发现：以羟苯磺酸钙组合葛根黄酮，治疗微循环障碍疾病，能够具有协同作用，达到了优势互补，提高疗效的作用。
发明内容
羟苯磺酸钙为国际上广泛使用的微血管循环改善剂，1997年载入欧洲药典，1998年载入英国药典。对微血管循环障碍(毛细血管循环障碍)引起的多种疾病，疗效确切，
葛根黄酮，尤其是葛根素具有抑制血小板聚集，降低血液粘度，改善微循环的作用，对人血清蛋白和大鼠晶状体蛋白的非酶糖基化有明显抑制作用。
本发明将羟苯磺酸钙与葛根黄酮组合应用来治疗微血管循环障碍疾病，特别是由糖尿病引起的视网膜病变等有着较好的协同作用，比单独使用效果更佳。基于上述发现，本发明提供一种用于治疗由微血管循环障碍引起的多种疾病的药物组合物及其制备方法。该组合物含有羟苯磺酸钙和葛根黄酮作为药物活性成分，可用于治疗由微血管循环障碍引起的多种疾病，特别的，主要用于糖尿病引起的视网膜病变，微循环障碍引起的心、脑、肾疾病，如肾小球动脉硬化症以及静脉曲张等综合症的治疗。
本发明所述葛根黄酮是从中药葛根中提取得到的含有黄酮类成分的提取物，该提取物由于提取工艺不同，所含黄酮类成分也不同，该提取物可以是葛根总黄酮，也可以是其中的一种葛根黄酮或其中的几种葛根黄酮的混合物。优选的葛根黄酮是葛根素(8-β-D-葡萄吡喃糖-4′，7-二羟基异黄酮)。
葛根黄酮作为药物应用有多年，可以从市场上买到，已经列入药典或国家药品标准，其制备方法有多种，在专利文献或其他文献中有大量的报道，属于现有技术，如：葛根黄酮通过粉碎、压榨、研磨、过筛、渗漉、萃取、水提、醇提、酯提、层析等方法对葛根进行加工得到、所得葛根黄酮可以是浸膏形式的物质，可以是干浸膏也可以是流浸膏，根据制剂的不同需要决定制成不同的浓度。
本发明也提供了葛根黄酮的制备方法，具体见实施例。
根据本发明，所述葛根黄酮是符合药物标准的产品，只要符合药物标准，能够作为药物应用，不管用什么方法制备的葛根黄酮都属于本发明的保护范围。
本发明的组合物，其中羟苯磺酸钙和葛根黄酮的重量配比为10-1000重量份的羟苯磺酸钙和10-1000重量份的葛根黄酮。
优选的羟苯磺酸钙和葛根黄酮的重量配比为100-500重量份的羟苯磺酸钙和100-500重量份的葛根黄酮。
最优选的羟苯磺酸钙和和葛根黄酮的重量配比为250重量份的羟苯磺酸钙和250重量份的葛根黄酮。
以上组成是按重量作为配比的，如大规模生产可以以kg为单位，或以t(吨)为单位；小规模制剂也可以以g为单位。重量可以增大或者减小，但各组成之间的重量配比的比例不变。
以上重量配比的比例是经过科学筛选得到的，对于特殊病人，如重症或轻症，肥胖或瘦小的病人，可以相应调整组成的量的配比，增加或减少不超过100％，药效不变。
本发明的组合物，以药物制剂形式存在，优选的是单位剂量的药物制剂形式，在制成药物制剂时可以制成任何可药用的剂型，这些剂型选自：片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、丸剂、散剂、膏剂、丹剂、混悬剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、贴剂。优选的是口服制剂形式，最佳优选的是片剂，胶囊剂，颗粒剂。
本发明的药物制剂，根据需要可以加入一些药物可接受的载体，可以采用制剂学常规技术制备该药物制剂，如将药物活性物质与药物可接受的载体混合。所述药物可接受的的载体选自：甘露醇、山梨醇、山梨酸或钾盐、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素A、维生素C、维生素E、维生素D、氮酮、 EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、丙二醇、乙醇、土温60-80、司班-80、蜂蜡、羊毛脂、液体石蜡、十六醇、没食子酸酯类、琼脂、三乙醇胺、碱性氨基酸、尿素、尿囊素、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的药物制剂在使用时根据病人的情况确定用法用量。
本发明的药物制剂，在制成药剂时，单位剂量的药剂可含有本发明的药物活性物质0.1-1000mg，其余为药学上可接受的载体。药学上可接受的载体以重量计可以是制剂总重量的0.1-99.9％。
本发明最优选的配方列在本发明实施例中。
本发明的组合物主要用于治疗由微血管循环障碍引起的多种疾病，特别用于糖尿病引起的视网膜病变，微循环障碍引起的心、脑、肾疾病，如肾小球动脉硬化症以及静脉曲张等综合症的治疗。
以下通过实验数据说明本发明的有益效果：
试验例1：羟苯磺酸钙和葛根黄酮组合物对大鼠血流动力学的影响
取大鼠，禁食12h后，快速尾静脉注射链脲霉素50mg·kG-1，72h后测定血糖值。选择血糖水平13mmol·L-1以上者，按体重随机分五组，模型组，正常组，葛根黄酮治疗组(A组)，羟苯磺酸钙治疗组(B组)，实施例6中所得羟苯磺酸钙和葛根黄酮组合物治疗组(A+B组)，每组8只，灌胃给药，给药量100mg·kG-1，qd，连续30d，动物分组及实验方法同上，摘大鼠眼球取血4ml，(肝素体外抗凝)，测定以下指标：(1)全血粘度(ηb)，(2)血浆粘度(ηb)，(3)红细胞压积(HCT)，(4)血沉(ESR)，试验结果如表1所示。
表1葛根提取物对STZ大鼠血流动力学的影响(x±s，n＝8)
| 组别 | 高切粘度(γ)(mPa.s) | 低切粘度(γ)(mPa.s) | 血浆粘度(mPa.s) | 红细胞压积％ |
| 模型组正常组A组B组A+B组 | 12.36±0.6810.13 ±0.5711.21±0.5811.08±0.6810.53±0.52 | 4.73 ±0.453.69 ±0.244.26±0.304.11±0.293.78±0.35 | 1.98 ±0.151.32 ±0.071.60±0.071.57±0.151.39±0.08 | 45.67±1.4341.23±0.8742.59±0.6842.67±0.7941.58±0.83 |
结论：由以上试验结果可知，与单独用药及模型组相比羟苯磺酸钙和葛根黄酮组合物治疗组，可明显降低大鼠全血高切粘度、低切粘度及血浆粘度，红细胞压积。由于高切血液粘度主要反映红细胞的变形能力，低切血液粘度主要反映红细胞的聚集能力，表明羟苯磺酸钙和葛根黄酮具有降低血液粘稠度、改善局部血液循环的协同药理作用，因此可用于治疗微血管循环障碍疾病，如糖尿病引起的视网膜病变等。
试验例2：羟苯磺酸钙和葛根素组合物治疗糖尿病视网膜病变疗效观察
II型糖尿病患者60例，符合WHO糖尿病诊断和分型标准，临床诊断为糖尿病视网膜病变，除外其他原因所致眼底改变。随机分为4组，分别为葛根素治疗组(A组)，羟苯磺酸钙治疗组(B组)，羟苯磺酸钙和葛根素组合物治疗组(A+B组)。
四组患者给予常规降血糖药物治疗的同时，治疗组A给予葛根素500mg，每日2次；治疗组B给予羟苯磺酸钙500mg，每日2次；治疗组A+B给予葛根素和羟苯磺酸钙各250mg，每日2次，以上药物均口服给药；对照组予弥克保500μg，每日1次，肌肉注射，3周为1个疗程，连用2个疗程。
4组患者均于治疗前后用彩色多普勒测定视网膜中央动静脉血流参数，治疗前后视网膜中央动脉的收缩峰值血流速度(PSV)、加速度(A)、舒张末期血流最大速度(EDV)以及视网膜中央静脉回流速度(CRV)结果如下表所示。
表2治疗前后视网膜中央动静脉血液流变学血参数比较(cm/s)
| 组别 | PSV | EDV | A | CRV | |
| 对昭组 | 治疗前治疗后 | 9.75±2.3810.13±1.83 | 3.11±0.953.39±1.28 | 90.35±22.1692.16±20.86 | 8.32±1.847.95±1.59 |
| A组 | 治疗前治疗后 | 9.68±2.8611.68±2.14 | 3.01±1.433.89±1.19 | 88.48±25.67100.57±19.86 | 8.54 ±2.397.37±1.97 |
| B组 | 治疗前治疗后 | 9.58±1.9911.58±2.45 | 3.17±1.313.91±1.56 | 89.27±21.83105.4±15.43 | 8.47±2.117.25±1.86 |
| A+B组 | 治疗前治疗后 | 9.73±2.5112.28±2.22 | 3.09±1.224.23±1.39 | 88.93±23.41113.21±15.77 | 8.41±2.296.71±2.16 |
由试验结果可知，各治疗组治疗前后视网膜中央动脉的收缩峰值血流速度(PSV)、加速度(A)、舒张末期血流最大速度(EDV)均增加，视网膜中央静脉回流速度(CRV)减慢。与羟苯磺酸钙和葛根素单独用药相比，复方给药组对视网膜中央动静脉血液流变学血参数的改变更加显著，揭示复方给药对视网膜微循环改善作用较单独给药为佳，说明两种药物具有很好的协同微循环改善作用，可以使用两药的复方来治疗糖尿病视网膜病变等微循环障碍疾病。
具体实施方式
下面通过具体实施方式对本发明做进一步说明，但并不意味着对本发明保护范围的限定。
实施例1
将原辅料分别过100目筛，取羟苯磺酸钙5g，葛根黄酮500g，加入微晶纤维素、羧甲基淀粉钠混合均匀，加入15％PVP适量制成软材，用16-24目筛制粒，湿颗粒于50-80℃干燥，16-24目筛整粒，加入硬脂酸镁混匀，测定颗粒中主药含量合格后，压片，制成2000片。
其中，葛根黄酮的提取方法如下：取葛根10kg，加6倍量水煎煮三次，第一次1.0小时，第二、三次为0.5小时，分别滤过，合并滤液，浓缩成相对密度为1.08～1.14(55℃)的清膏，将清膏搅拌下加入2.8倍的乙醇，搅匀，加热至60℃，静置24h，滤过，减压回收乙醇，浓缩成稠膏状，85℃以下真空干燥得干膏1.25kg，将干膏研细备用。通过紫外分光光度法测定，干膏中葛根黄酮所占的百分比约为40％，干膏中葛根黄酮的量约为500g。
实施例2
将原辅料分别过100目筛，取羟苯磺酸钙500g，葛根黄酮5g，加入微晶纤维素、羧甲基淀粉钠混合均匀，加入15％PVP适量制成软材，用16-24目筛制粒，湿颗粒于50-80℃通风干燥，16-24目筛整粒，加入硬脂酸镁混匀，测定颗粒中主药含量合格后，上胶囊分装机包封，制成1000粒。
其中，葛根黄酮的提取方法如实施例1所述。
实施例3
将原辅料分别过100目筛，取羟苯磺酸钙100g，葛根素500g，加入微晶纤维素、羧甲基淀粉钠混合均匀，加入15％PVP适量制成软材，用16-24目筛制粒，湿颗粒于50-80℃通风干燥，16-24目筛整粒，加入硬脂酸镁混匀，测定颗粒中主药含量合格后，压片，制成2000粒。
实施例4
将原辅料分别过100目筛，取羟苯磺酸钙500g，葛根素100g，加入微晶纤维素、羧甲基淀粉钠混合均匀，加入15％PVP适量制成软材用16-24目筛制粒，湿颗粒于50-80℃通风干燥，16-24目筛整粒，加入硬脂酸镁混匀，测定颗粒中主药含量合格后，上胶囊分装机包封，制成1000粒。
实施例5
将原辅料分别过100目筛，取羟苯磺酸钙250g，葛根素250g，加入微晶纤维素、羧甲基淀粉钠混合均匀，加入15％PVP适量制成软材，用16-24目筛制粒，湿颗粒于50-80℃通风干燥，16-24目筛整粒，加入硬脂酸镁混匀，测定颗粒中主药含量合格后，压片，制成2000粒。
实施例6
将原辅料分别过100目筛，取羟苯磺酸钙250g，葛根黄酮250g，加入微晶纤维素、羧甲基淀粉钠混合均匀，加入15％PVP适量制成软材，用16-24目筛制粒，湿颗粒于50-80℃通风干燥，16-24目筛整粒，加入硬脂酸镁混匀，测定颗粒中主药含量合格后，上胶囊分装机包封，制成1000粒。
其中，葛根黄酮的提取方法如实施例1所述。
Claims (10)
1、一种用于治疗由微血管循环障碍引起的多种疾病的药物组合物，其特征在于：含有羟苯磺酸钙和葛根黄酮作为药物活性成分，其中羟苯磺酸钙和葛根黄酮的重量配比为：10-1000重量份的羟苯磺酸钙和10-1000重量份的葛根黄酮。
2、根据权利要求1所述的组合物，其特征在于：其中羟苯磺酸钙和葛根黄酮的重量配比为：100-500重量份的羟苯磺酸钙和100-500重量份的葛根黄酮。
3、根据权利要求1所述的组合物，其特征在于：其中羟苯磺酸钙和和葛根黄酮的重量配比为：250重量份的羟苯磺酸钙和250重量份的葛根黄酮。
4、根据权利要求1-3任何一项组合物，其特征在于：其中葛根黄酮可以是从葛根中提取得到的葛根总黄酮，也可以是一种葛根黄酮或几种葛根黄酮的混合物。
5、根据权利要求1-3任何一项组合物，其特征在于：其中葛根黄酮是葛根素。
6、根据权利要求1-3任何一项组合物，其特征在于：选自如下药物剂型，片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、丸剂、散剂、膏剂、丹剂、混悬剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、贴剂。
7、根据权利要求6的组合物，其特征在于：是片剂或胶囊剂。
8、根据权利要求1所述的组合物，其特征在于：根据需要还可含有药用辅料，如微晶纤维素、羧甲基淀粉钠、淀粉、糊精、PVP、硬脂酸镁等。
9、权利要求1的组合物在制备治疗由微血管循环障碍引起的疾病的药物中的应用。
10、权利要求9的应用，其特征在于：由微血管循环障碍引起的疾病是糖尿病引起的视网膜病变，微循环障碍引起的心、脑、肾疾病。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100813055A CN100417389C (zh) | 2006-05-16 | 2006-05-16 | 一种用于治疗微血管循环障碍疾病的药物组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100813055A CN100417389C (zh) | 2006-05-16 | 2006-05-16 | 一种用于治疗微血管循环障碍疾病的药物组合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1857297A true CN1857297A (zh) | 2006-11-08 |
| CN100417389C CN100417389C (zh) | 2008-09-10 |
Family
ID=37296285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100813055A Expired - Fee Related CN100417389C (zh) | 2006-05-16 | 2006-05-16 | 一种用于治疗微血管循环障碍疾病的药物组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100417389C (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110141611A (zh) * | 2019-04-01 | 2019-08-20 | 海南林恒制药股份有限公司 | 一种羟苯磺酸钙固体制剂及其应用 |
| CN115581681A (zh) * | 2022-06-10 | 2023-01-10 | 海南林恒制药股份有限公司 | 一种新型羟苯磺酸钙胶囊剂及其制备方法 |
| CN116019824A (zh) * | 2023-03-29 | 2023-04-28 | 吉林华康药业股份有限公司 | 一种用于防治微循环障碍的中药组合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704048A (zh) * | 2004-05-25 | 2005-12-07 | 孙明杰 | 复方羟苯磺酸钙 |
-
2006
- 2006-05-16 CN CNB2006100813055A patent/CN100417389C/zh not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110141611A (zh) * | 2019-04-01 | 2019-08-20 | 海南林恒制药股份有限公司 | 一种羟苯磺酸钙固体制剂及其应用 |
| CN115581681A (zh) * | 2022-06-10 | 2023-01-10 | 海南林恒制药股份有限公司 | 一种新型羟苯磺酸钙胶囊剂及其制备方法 |
| CN116019824A (zh) * | 2023-03-29 | 2023-04-28 | 吉林华康药业股份有限公司 | 一种用于防治微循环障碍的中药组合物 |
| CN116019824B (zh) * | 2023-03-29 | 2023-05-30 | 吉林华康药业股份有限公司 | 一种用于防治微循环障碍的中药组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100417389C (zh) | 2008-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106074496A (zh) | 大麻酚类化合物在制备治疗痛风药物中的应用 | |
| CN1582159A (zh) | 增加了溶解度的黄烷醇木脂体制备物 | |
| CN100417389C (zh) | 一种用于治疗微血管循环障碍疾病的药物组合物及其制备方法 | |
| CN1679706A (zh) | 一种由三七、红景天制成的治疗心脑血管疾病的药物制剂及其制备方法 | |
| CN1733081A (zh) | 一种具有养血安神的中药制剂及其制备方法 | |
| CN1907432A (zh) | 天麻多糖在保健品和药物中的应用 | |
| JP2021512997A (ja) | 分離された防風多糖及びその用途 | |
| CN104069194B (zh) | 一种具有抗癌作用的中药组合物及其制备方法和用途 | |
| CN103083370B (zh) | 沙棘总黄酮的用途 | |
| CN1762341A (zh) | 治疗心脑血管疾病、肝脏疾病的丹参酚酸复合物及其应用 | |
| CN1679701A (zh) | 一种由三七、红花制成的治疗心脑血管疾病的药物制剂及其制备方法 | |
| CN1301707C (zh) | 一种注射用丹红冻干粉针制剂 | |
| CN106063794A (zh) | 连翘苷、其衍生物、连翘苷与连翘脂素组合物在制备预防或/和治疗肝损伤药物中的应用 | |
| CN1899329A (zh) | 具有降血脂功效的药物组合物 | |
| CN101745008B (zh) | 一种人参,麦冬,五味子的提取方法及其制剂 | |
| CN1593444A (zh) | 治疗心脑血管疾病的组方药物 | |
| CN1861087A (zh) | 一种高纯度野黄芩苷药物组合物及其在制备心、脑血管药物方面的医药用途 | |
| CN108888672A (zh) | 含有蚌肉多糖和宝乐果的组合物及其制备方法和应用 | |
| JP2021512998A (ja) | 分離された白茅根多糖及びその用途 | |
| CN108671074A (zh) | 预防和/或治疗心脑血管疾病的银杏叶枸杞复方口服液及其制备方法 | |
| CN101744990B (zh) | 一种人参，麦冬，五味子的单独提取方法及其制剂 | |
| CN1895346A (zh) | 一种治疗心脑血管疾病的中药制剂及制备方法 | |
| CN1795927A (zh) | 红花总黄酮磷脂复合物及其制备方法 | |
| CN1907278A (zh) | 用于治疗心脑血管疾病的药物组合物 | |
| CN1742766A (zh) | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: Tianchuang Technology Building No. 8 Beijing Haidian District color charge Fang Lu room 720 zip code: 100080 Co-patentee after: Jilin A-Think Pharmaceutical Co.,Ltd. Patentee after: Beijing Guodan Medicine Technology Development Co.,Ltd. Address before: No. 8, Gucheng West Road, Beijing, Shijingshan District: 100043 Co-patentee before: Jilin A-Think Pharmaceutical Co.,Ltd. Patentee before: Beijing Guodan Medicine Technology Development Co.,Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Tianchuang Technology Building No. 8 Beijing Haidian District color charge Fang Lu room 720 zip code: 100080 Co-patentee after: Jilin Yixin pharmaceutical Limited by Share Ltd. Patentee after: Beijing Guodan Medicine Technology Development Co.,Ltd. Address before: Tianchuang Technology Building No. 8 Beijing Haidian District color charge Fang Lu room 720 zip code: 100080 Co-patentee before: Jilin A-Think Pharmaceutical Co.,Ltd. Patentee before: Beijing Guodan Medicine Technology Development Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20090213 Address after: No. 1, one heart road, Shuangyang Economic Development Zone, Jilin, Changchun: 130616 Patentee after: Jilin Yixin pharmaceutical Limited by Share Ltd. Address before: Tianchuang Technology Building No. 8 Beijing Haidian District color charge Fang Lu room 720 zip code: 100080 Co-patentee before: Jilin Yixin pharmaceutical Limited by Share Ltd. Patentee before: Beijing Guodan Medicine Technology Development Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: JILIN YIXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING GUO DAN DRUG TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20090213 |
|
| C56 | Change in the name or address of the patentee |
Owner name: JILIN A-THINK PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: JILIN YIXIN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 130616 Jilin province Changchun Shuangyang Economic Development Zone on the road No. 1 Patentee after: SINOPHARM A-THINK PHARMACEUTICAL Co.,Ltd. Address before: 130616 Jilin province Changchun Shuangyang Economic Development Zone on the road No. 1 Patentee before: Jilin Yixin pharmaceutical Limited by Share Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Guoyao Yixin Pharmaceutical Co.,Ltd. Person in charge of patentsThe principal of patent Document name: Notice of termination of patent right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080910 |